Galera to Present at Piper Sandler Annual Healthcare Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that President and CEO Mel Sorensen, M.D., will present at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 11:10 a.m. E.T.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Galera Therapeutics, Inc. (Nasdaq: GRTX) announced that President and CEO Mel Sorensen, M.D., will present at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 11:10 a.m. E.T. A live webcast will be available on Galera's Investors page and archived for 30 days post-event. Galera is focused on developing innovative treatments to enhance cancer radiotherapy, notably its product candidates avasopasem manganese and rucosopasem manganese, aimed at reducing toxicities and improving efficacy in cancer treatments.
Details
News Market Reaction – GRTX
The recorded move for GRTX in the trading session of this news was -1.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at the Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 11:10 a.m. E.T.
A live webcast of the presentation will be accessible from the Investors page of Galera’s website, investors.galeratx.com. An archived version of the webcast will be available in the News & Events section of the Investors page of Galera’s website for 30 days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s selective dismutase mimetic product candidate avasopasem manganese (avasopasem, or GC4419) is being evaluated for radiotherapy-induced toxicities. The Company’s second product candidate, rucosopasem manganese (rucosopasem, or GC4711), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Galera is headquartered in Malvern, PA. For more information, please visit www.galeratx.com.
Investor Contacts:
Christopher Degnan
Galera Therapeutics, Inc.
610-725-1500
cdegnan@galeratx.com
William Windham
Solebury Strategic Communications
646-378-2946
wwindham@soleburystrat.com
Media Contact:
Zara Lockshin
Solebury Strategic Communications
330-417-6250
zlockshin@soleburystrat.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.